01 / IDENTITY
Compound Profile
SEQUENCE
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
ORIGIN
Isolated C-terminal fragment of human GH (residues 176–191). Contains the fat-mobilizing domain with disulfide bridge intact. Developed by Metabolic Pharmaceuticals (Australia).
MECHANISM
Binds β3-adrenergic receptors in adipose tissue. Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) — without engaging IGF-1 axis or GH receptor pathways.
PRIMARY EFFECT
Targeted lipolysis — preferentially mobilizes visceral and subcutaneous adipose fat. Does NOT affect glucose metabolism or cause insulin resistance like full-length GH.
KEY DISTINCTION
Retains the fat-burning domain of GH with NONE of the anabolic, glucose, or IGF-1 side effects. No water retention, no insulin resistance, no musculoskeletal overgrowth.
SECONDARY BENEFIT
Chondroprotective — FDA granted Orphan Drug designation for osteoarthritis treatment. Stimulates cartilage and bone repair independent of fat loss effects.
Why AOD-9604 over GH for fat loss: Full-length GH causes IGF-1 elevation, insulin resistance, and water retention at fat-burning doses. AOD-9604 isolates only the lipolytic domain — you get the fat loss effect with the safety profile of a peptide, not a hormone.
02 / RESEARCH HISTORY
Development Timeline
1990s
Researchers at Monash University (Australia) identify that the C-terminal fragment of hGH (residues 176–191) contains the fat-mobilizing domain. Full GH is too broad — this fragment isolates the mechanism.
2001
Metabolic Pharmaceuticals (Australia) begins clinical development. Phase I trials confirm safety and no effect on blood glucose or IGF-1 — validating the fragment approach.
2004–2007
Phase IIa/IIb trials in obese adults. Oral AOD-9604 (MK-0677) shows statistically significant fat reduction vs. placebo. SC formulation advances as more bioavailable route.
2014
FDA grants Orphan Drug designation for AOD-9604 in osteoarthritis — recognizing cartilage repair mechanism. Expands clinical profile beyond metabolic use.
2015–Present
Compounding pharmacies adopt AOD-9604 as part of metabolic/anti-obesity protocols. Widely stacked with GLP-1 agonists, peptides, and lifestyle interventions. Ongoing cartilage research continues.
03 / BENEFITS & MECHANISMS
Research-Supported Effects
01
Targeted Lipolysis — Visceral & Subcutaneous Fat
Binds β3-adrenergic receptors in adipose tissue to activate hormone-sensitive lipase (HSL). Preferentially breaks down stored triglycerides into free fatty acids — especially effective on visceral (deep belly) fat that resists diet and exercise.
02
Lipogenesis Inhibition — Stops Fat Storage
Simultaneously inhibits acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in fat synthesis. Dual action: breaks down existing fat AND prevents new fat from being stored from dietary intake.
03
Glucose & Insulin Neutral — No Metabolic Penalty
Unlike full-length hGH, AOD-9604 does NOT activate IGF-1 pathways or impair insulin sensitivity. Fasting glucose and HbA1c remain stable. Critical distinction for metabolic syndrome patients and diabetics.
04
Chondroprotection — Cartilage & Joint Repair
Independent mechanism via TGF-β stimulation. Promotes proteoglycan synthesis in articular cartilage, reduces joint space narrowing in animal osteoarthritis models. FDA Orphan Drug status validates this pathway. Particularly valuable stacked with BPC-157 or TB-500.
05
Clean Tolerability Profile
No water retention (no aldosterone pathway activation). No carpal tunnel risk. No gynecomastia risk. No suppression of endogenous GH. No impact on thyroid panel. Injection site reactions are mild and transient.
AOD-9604 ✓
Fat breakdown (lipolysis) ✓
Lipogenesis inhibition ✓
Cartilage repair ✓
Glucose neutral ✓
No IGF-1 elevation ✓
No water retention ✓
Full hGH — Fat Loss Dose
Fat breakdown ✓
IGF-1 elevation (anabolic) ⚠
Insulin resistance risk ⚠
Water retention ⚠
Carpal tunnel risk ⚠
Expensive + controlled ⚠
04 / RECONSTITUTION
Vial Preparation
STANDARD VIAL — 10mg
10mg vial + 3.0 mL (300 units) bacteriostatic water
Concentration: 33.3 mcg per unit (0.01 mL)
| DOSE |
MCG |
UNITS (on syringe) |
VOLUME |
| LOW |
250mcg |
7.5 units |
0.075 mL |
| STANDARD |
500mcg |
15 units |
0.15 mL |
| HIGH |
1000mcg |
30 units |
0.30 mL |
Storage: Lyophilized powder stable at room temp up to 6 months. Refrigerate (2–8°C) for long-term storage. After reconstitution: refrigerate, use within 30 days. Protect from light. Do NOT freeze reconstituted vial.
05 / DOSING PROTOCOL
Dose Ranges
| LEVEL |
DOSE |
FREQUENCY |
USE CASE |
| LOW |
250mcg / day |
Daily |
Sensitive individuals, first cycle, maintenance |
| STANDARD |
500mcg / day |
Daily |
Active fat loss phase — most users start here |
| HIGH |
1000mcg / day |
Daily |
Accelerated protocol, clinical trial dose range |
Oral vs. SC: Early Metabolic Pharmaceuticals trials used oral delivery — SC injection is significantly more bioavailable and is the standard for compounding pharmacy protocols. Oral AOD-9604 requires 10× higher doses to achieve equivalent plasma levels.
GLP-1 Stack Protocol: AOD-9604 + Semaglutide or Tirzepatide is a powerful combination. GLP-1s reduce appetite and caloric intake; AOD-9604 drives direct lipolysis. The two mechanisms are additive, not redundant. Standard: 500mcg AOD-9604 AM fasted + GLP-1 injection per individual protocol.
06 / TIMING & ADMINISTRATION
Injection Protocol
OPTIMAL WINDOW
Morning — Fasted State
WHY FASTED
Lipolysis is maximized when insulin is at baseline. Eating raises insulin → insulin blocks HSL (the fat-burning enzyme) → AOD-9604 effectiveness drops significantly. Inject 30–60 min before breakfast.
WAIT POST-INJECTION
Wait 30–60 minutes before eating. During this window, free fatty acids mobilized by AOD-9604 enter circulation and are available for oxidation (especially if light cardio is performed).
INJECTION SITE
Subcutaneous — abdomen (periumbilical region preferred for visceral fat targeting), outer thigh, or lateral deltoid. Rotate sites to prevent fibrosis.
PRE-WORKOUT OPTION
Some protocols use 30–45 min pre-fasted cardio. The mobilized fatty acids serve as fuel during exercise — a potent combination for body recomposition. Not required; morning fasted alone is effective.
CARTILAGE PROTOCOL
For joint/cartilage indication: timing less critical — AM or PM both effective. Consistent daily dosing is more important than precise timing window.
07 / BIOMARKER MONITORING
Recommended Lab Panel
METABOLIC — PRIMARY EFFECT MARKERS
| MARKER | CLINICAL RANGE | OPTIMAL TARGET | NOTES |
|---|
| Fasting Glucoseglucose (fasting) |
CLINICAL70–99 mg/dL |
OPTIMAL72–90 mg/dL |
Should remain unchanged on AOD-9604 — divergence suggests stacking issue |
| Fasting Insulininsulin (fasting) |
CLINICAL2–25 µIU/mL |
OPTIMAL3–8 µIU/mL |
Stability confirms no IR development; improvement expected over fat loss cycle |
| HbA1chemoglobin A1c |
CLINICAL<5.7% |
OPTIMAL<5.3% |
Baseline; should not elevate. Fat loss may improve over course of cycle. |
| HOMA-IRcalculated index |
CLINICAL<2.5 |
OPTIMAL<1.5 |
Insulin resistance index — calculate from glucose + insulin. Should improve. |
SAFETY — GH AXIS CONFIRMATION
| MARKER | CLINICAL RANGE | OPTIMAL TARGET | NOTES |
|---|
| IGF-1insulin-like growth factor 1 |
CLINICALAge-adjusted |
OPTIMALStable |
Should NOT elevate — confirms AOD-9604 is not activating GH receptor axis |
| Lipid Paneltotal cholesterol, LDL, HDL, TG |
CLINICALStandard reference |
OPTIMALTG <80 mg/dL |
TG and LDL may improve as visceral fat mobilizes. Monitor for trajectory. |
| CRP (hs)high-sensitivity C-reactive protein |
CLINICAL<3.0 mg/L |
OPTIMAL<1.0 mg/L |
Visceral fat reduction drives systemic inflammation down — track improvement |
JOINT / CARTILAGE (if using for osteoarthritis)
| MARKER | CLINICAL RANGE | NOTES |
|---|
| Cartilage Oligomeric Matrix ProteinCOMP |
CLINICAL<10 µg/mL |
Elevated in active cartilage breakdown — reduction indicates chondroprotection |
| MRI Joint Assessmentradiographic |
CLINICAL— |
Pre/post MRI at 12+ weeks for cartilage volume and joint space changes |
08 / CYCLE PROTOCOL
Administration Schedule
FREQUENCY
Daily (7 days/week). Consistent daily dosing outperforms 5-on/2-off for fat loss — metabolic effect is cumulative.
OFF PERIOD
4–8 weeks off between cycles. No clinical evidence of tolerance, but cycling prevents receptor accommodation and allows metabolic assessment.
GOLD STACK: FAT LOSS
AOD-9604 500mcg AM + Semaglutide (per protocol) + MOTS-c 5mg AM. Triple metabolic attack: lipolysis + appetite + mitochondrial efficiency.
GOLD STACK: JOINT + FAT
AOD-9604 500mcg + BPC-157 500mcg + TB-500 2mg (2x/week). Fat mobilization with full joint and tissue repair support.
REQUIRES
Reconstitution with BAC water · Precise dosing with Apex V3 Pen · Refrigeration post-reconstitution
⚠ Research reference only. AOD-9604 is not FDA-approved for human therapeutic use. Information sourced from published clinical and preclinical literature. Consult a qualified medical provider before use.